Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells

Mitchel Hoffman, Abraham Mittelman, Brad Dworkin, William Rosenthal, Deborah Beneck, Elizabeth Gafney, Zalmen Arlin, Daniel Levitt, Eckhard Podack

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Immunotherapy with recombinant interleukin-2 (rIL-2) and lymphokine-activated killer cells (LAK) has become a new form of therapy that has been shown to induce remissions in patients with renal cell carcinoma and melanoma. Despite encouraging results, this form of therapy has been associated with increasing toxicity, often requiring therapy in an intensive-care unit. In this report severe intrahepatic cholestasis occurred in two patients receiving rIL-2 and LAK cells. This form of cholestasis appeared to be directly related to rIL-2 administration at a doses of 2×106 U/m2 and 3x106 U/m2 t.i.d. A liver biopsy showed moderate hepatocellular bile stasis, with lobular and portal inflamation. All other studies for potential cause of this cholestasis were negative, including studies for metastatic disease. When therapy was discontinued, evidence for cholestasis and bile stasis resolved. We conclude that rIL-2 is a drug with a potential to induce severe hepatic injury that is reversible upon cessation of therapy with rIL-2. Further care should be exercised when rIL-2 is administered to patients with abnormal liver function.

Original languageEnglish
Pages (from-to)175-178
Number of pages4
JournalJournal of Cancer Research and Clinical Oncology
Volume115
Issue number2
DOIs
StatePublished - Apr 1 1989
Externally publishedYes

Fingerprint

Intrahepatic Cholestasis
Lymphokine-Activated Killer Cells
Interleukin-2
Cholestasis
Bile
Liver
Therapeutics
Renal Cell Carcinoma
Immunotherapy
Intensive Care Units
Melanoma
Biopsy
Wounds and Injuries
Pharmaceutical Preparations

Keywords

  • Cholestasis
  • Interleukin-2
  • LAK cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells. / Hoffman, Mitchel; Mittelman, Abraham; Dworkin, Brad; Rosenthal, William; Beneck, Deborah; Gafney, Elizabeth; Arlin, Zalmen; Levitt, Daniel; Podack, Eckhard.

In: Journal of Cancer Research and Clinical Oncology, Vol. 115, No. 2, 01.04.1989, p. 175-178.

Research output: Contribution to journalArticle

Hoffman, M, Mittelman, A, Dworkin, B, Rosenthal, W, Beneck, D, Gafney, E, Arlin, Z, Levitt, D & Podack, E 1989, 'Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells', Journal of Cancer Research and Clinical Oncology, vol. 115, no. 2, pp. 175-178. https://doi.org/10.1007/BF00397920
Hoffman, Mitchel ; Mittelman, Abraham ; Dworkin, Brad ; Rosenthal, William ; Beneck, Deborah ; Gafney, Elizabeth ; Arlin, Zalmen ; Levitt, Daniel ; Podack, Eckhard. / Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells. In: Journal of Cancer Research and Clinical Oncology. 1989 ; Vol. 115, No. 2. pp. 175-178.
@article{71c5db0505dd498a99aa897c226b230c,
title = "Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells",
abstract = "Immunotherapy with recombinant interleukin-2 (rIL-2) and lymphokine-activated killer cells (LAK) has become a new form of therapy that has been shown to induce remissions in patients with renal cell carcinoma and melanoma. Despite encouraging results, this form of therapy has been associated with increasing toxicity, often requiring therapy in an intensive-care unit. In this report severe intrahepatic cholestasis occurred in two patients receiving rIL-2 and LAK cells. This form of cholestasis appeared to be directly related to rIL-2 administration at a doses of 2×106 U/m2 and 3x106 U/m2 t.i.d. A liver biopsy showed moderate hepatocellular bile stasis, with lobular and portal inflamation. All other studies for potential cause of this cholestasis were negative, including studies for metastatic disease. When therapy was discontinued, evidence for cholestasis and bile stasis resolved. We conclude that rIL-2 is a drug with a potential to induce severe hepatic injury that is reversible upon cessation of therapy with rIL-2. Further care should be exercised when rIL-2 is administered to patients with abnormal liver function.",
keywords = "Cholestasis, Interleukin-2, LAK cells",
author = "Mitchel Hoffman and Abraham Mittelman and Brad Dworkin and William Rosenthal and Deborah Beneck and Elizabeth Gafney and Zalmen Arlin and Daniel Levitt and Eckhard Podack",
year = "1989",
month = "4",
day = "1",
doi = "10.1007/BF00397920",
language = "English",
volume = "115",
pages = "175--178",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells

AU - Hoffman, Mitchel

AU - Mittelman, Abraham

AU - Dworkin, Brad

AU - Rosenthal, William

AU - Beneck, Deborah

AU - Gafney, Elizabeth

AU - Arlin, Zalmen

AU - Levitt, Daniel

AU - Podack, Eckhard

PY - 1989/4/1

Y1 - 1989/4/1

N2 - Immunotherapy with recombinant interleukin-2 (rIL-2) and lymphokine-activated killer cells (LAK) has become a new form of therapy that has been shown to induce remissions in patients with renal cell carcinoma and melanoma. Despite encouraging results, this form of therapy has been associated with increasing toxicity, often requiring therapy in an intensive-care unit. In this report severe intrahepatic cholestasis occurred in two patients receiving rIL-2 and LAK cells. This form of cholestasis appeared to be directly related to rIL-2 administration at a doses of 2×106 U/m2 and 3x106 U/m2 t.i.d. A liver biopsy showed moderate hepatocellular bile stasis, with lobular and portal inflamation. All other studies for potential cause of this cholestasis were negative, including studies for metastatic disease. When therapy was discontinued, evidence for cholestasis and bile stasis resolved. We conclude that rIL-2 is a drug with a potential to induce severe hepatic injury that is reversible upon cessation of therapy with rIL-2. Further care should be exercised when rIL-2 is administered to patients with abnormal liver function.

AB - Immunotherapy with recombinant interleukin-2 (rIL-2) and lymphokine-activated killer cells (LAK) has become a new form of therapy that has been shown to induce remissions in patients with renal cell carcinoma and melanoma. Despite encouraging results, this form of therapy has been associated with increasing toxicity, often requiring therapy in an intensive-care unit. In this report severe intrahepatic cholestasis occurred in two patients receiving rIL-2 and LAK cells. This form of cholestasis appeared to be directly related to rIL-2 administration at a doses of 2×106 U/m2 and 3x106 U/m2 t.i.d. A liver biopsy showed moderate hepatocellular bile stasis, with lobular and portal inflamation. All other studies for potential cause of this cholestasis were negative, including studies for metastatic disease. When therapy was discontinued, evidence for cholestasis and bile stasis resolved. We conclude that rIL-2 is a drug with a potential to induce severe hepatic injury that is reversible upon cessation of therapy with rIL-2. Further care should be exercised when rIL-2 is administered to patients with abnormal liver function.

KW - Cholestasis

KW - Interleukin-2

KW - LAK cells

UR - http://www.scopus.com/inward/record.url?scp=0024544295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024544295&partnerID=8YFLogxK

U2 - 10.1007/BF00397920

DO - 10.1007/BF00397920

M3 - Article

C2 - 2785519

AN - SCOPUS:0024544295

VL - 115

SP - 175

EP - 178

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 2

ER -